Fycompa 2 mg contains perampanel, a novel antiepileptic agent that works as a selective, non‑competitive antagonist of the AMPA subtype of glutamate receptors. By blocking excitatory neurotransmission mediated by AMPA receptors, perampanel reduces neuronal hyperexcitability associated with seizures. Fycompa is approved as an adjunctive therapy for partial-onset seizures (with or without secondary generalization) and primary generalized tonic-clonic seizures in patients with epilepsy. The 2 mg strength is often used as a starting dose to establish tolerance and minimize adverse effects before gradually increasing to the therapeutic maintenance dose.

The usual dosing regimen begins with 2 mg taken orally once daily, preferably at bedtime, to reduce the potential for dizziness or drowsiness. Based on clinical response and tolerability, the dose may be increased by 2 mg increments at weekly intervals to a maximum of 8 to 12 mg per day as prescribed. Perampanel can be taken with or without food, but consistency is recommended. Do not abruptly stop taking Fycompa, as this may increase the risk of seizures; if discontinuation is necessary, taper slowly under medical supervision. Because perampanel is metabolized by the liver, dose adjustments may be needed in patients with hepatic impairment or those taking strong CYP3A inducers.

Common side effects include dizziness, drowsiness, fatigue, irritability, headache, ataxia (loss of coordination), and weight gain. More serious adverse events such as falls, aggression, hostility, anger, anxiety, or suicidal thoughts have been reported. Patients and caregivers should monitor for mood or behavioral changes and report these to a healthcare provider promptly. Fycompa may impair the ability to perform hazardous activities like driving or operating machinery. Use is not recommended in pregnancy unless the potential benefits outweigh risks; consult a doctor if pregnant or planning to become pregnant. For more details and to purchase Fycompa 2 mg, please visit: Fycompa 2 Mg.